Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Cobimetinib

    Client Email Product

    Cobimetinib

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    0

    US DMFs Filed

    US DMFs Filed

    0

    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    0

    API REF. PRICE (USD / KG)

    0

    API Market Place

    1
    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    1
    Europe

    Europe

    3
    Canada

    Canada

    1
    Australia

    Australia

    2
    South Africa

    South Africa

    1
    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    26.00

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS
    99
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    13

    USFDA Exclusivities

    4
    DIGITAL CONTENT

    Blog #PharmaFlow

    1

    News

    16
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    FDA Approves Oral MEK Inhibitor Cobimetinib Histiocytic Neoplasms Led by MSKCC
    FDA Approves Oral MEK Inhibitor Cobimetinib Histiocytic Neoplasms Led by MSKCC

    https://www.mskcc.org/news-releases/fda-approves-oral-mek-inhibitor-cobimetinib-histiocytic-neoplasms-research-led-msk-cancer

    MSKCC
    01 Nov 2022
    Share Share
    Revolution Medicines to Present Interim Data at ENA 2020 Ph 1b/2 Trial RMC-4630
    Revolution Medicines to Present Interim Data at ENA 2020 Ph 1b/2 Trial RMC-4630

    https://www.globenewswire.com/news-release/2020/10/12/2106773/0/en/Revolution-Medicines-to-Present-Interim-Data-at-ENA-2020-from-Phase-1b-2-Clinical-Trial-Combining-RMC-4630-with-Cobimetinib-for-RAS-Addicted-Solid-Tumors.html

    GLOBENEWSWIRE
    12 Oct 2020
    Share Share
    Roche's phase III IMspire150 study of Tecentriq plus Cotellic & Zelboraf
    Roche's phase III IMspire150 study of Tecentriq plus Cotellic & Zelboraf

    http://www.pharmabiz.com/NewsDetails.aspx?aid=119938&sid=2

    PHARMABIZ
    13 Dec 2019
    Share Share
    REVOLUTION Medicines Announces Dosing Patient in RMC-4630-02 with RMC-4630
    REVOLUTION Medicines Announces Dosing Patient in RMC-4630-02 with RMC-4630

    https://www.prnewswire.com/news-releases/revolution-medicines-announces-dosing-of-first-patient-in-rmc-4630-02-a-phase-1b2-trial-combining-rmc-4630-with-a-mek-inhibitor-300919270.html

    PR NEWSWIRE
    18 Sep 2019
    Share Share
    Roche/Exelixis' Cotellic fizzles in pivotal melanoma study
    Roche/Exelixis' Cotellic fizzles in pivotal melanoma study

    https://endpts.com/roche-exelixis-cotellic-fizzles-in-pivotal-melanoma-study/

    Natalie Grover ENDPTS
    21 Jun 2019
    Share Share
    Novartis wins key adjuvant Taf/Mek approval in Europe
    Novartis wins key adjuvant Taf/Mek approval in Europe

    http://www.pmlive.com/pharma_news/novartis_wins_key_adjuvant_tafmek_approval_in_europe_1250603

    Phil Taylor PM LIVE
    29 Aug 2018
    Share Share
    TESARO Collaborates to Evaluate ZEJULA® With Anti-PD-L1 therapy & MEK Inhibitor
    TESARO Collaborates to Evaluate ZEJULA® With Anti-PD-L1 therapy & MEK Inhibitor

    https://globenewswire.com/news-release/2018/06/05/1516974/0/en/TESARO-Announces-Collaboration-to-Evaluate-ZEJULA-in-Combination-With-Anti-PD-L1-Cancer-Immunotherapy-and-MEK-Inhibitor-in-Platinum-Sensitive-Ovarian-Cancer.html

    GLOBENEWSWIRE
    05 Jun 2018
    Share Share
    Greek Health Minister Takes Issue With Roche's Withdrawal of Cancer Medicine
    Greek Health Minister Takes Issue With Roche's Withdrawal of Cancer Medicine

    http://raps.org/Regulatory-Focus/News/2017/10/31/28788/Greek-Health-Minister-Takes-Issue-With-Roches-Withdrawal-of-Cancer-Medicine-Due-to-Mandatory-Discount/?utm_source=Email&utm_medium=Informz&utm_campaign=Informz-Emails

    Zachary Brennan RAPS
    01 Nov 2017
    Share Share
    Anvisa Suspends Roche's Trade in lot B1009M8 of The Medicinal Product Cotellic (hemifumarate of cobimetinib)
    Anvisa Suspends Roche's Trade in lot B1009M8 of The Medicinal Product Cotellic (hemifumarate of cobimetinib)

    https://www.pharmacompass.com/pdf/news/anvisa-suspends-roches-trade-in-lot-b1009m8-of-the-medicinal-product-cotellic-hemifumarate-of-cobimetinib-1494564186.pdf

    ANVISA
    11 May 2017
    Share Share
    Enforcement Report - Week of April 12, 2017
    Enforcement Report - Week of April 12, 2017

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-12-2017-1491972590.pdf

    FDA
    12 Apr 2017
    Share Share
    Hoffmann-La Roche Ltd. Recalls Cobimetinib Fumarate
    Hoffmann-La Roche Ltd. Recalls Cobimetinib Fumarate

    http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/62494r-eng.php

    HEALTH CANADA
    21 Mar 2017
    Share Share
    Novartis wins CHMP nod for drug combo against some lung cancers
    Novartis wins CHMP nod for drug combo against some lung cancers

    http://www.reuters.com/article/us-novartis-chmp-recommendation-idUSKBN1631G5?rpc=401&

    John Miller REUTERS
    25 Feb 2017
    Share Share
    Competition Stalls Roche Margin Growth; Drugmaker Commits to Diabetes Unit
    Competition Stalls Roche Margin Growth; Drugmaker Commits to Diabetes Unit

    http://www.reuters.com/article/us-roche-results-idUSKBN15G3H5

    John Miller REUTER
    02 Feb 2017
    Share Share
    Roche pushes Tecentriq combos into PhIII melanoma trials
    Roche pushes Tecentriq combos into PhIII melanoma trials

    http://www.pharmatimes.com/news/roche_pushes_tecentriq_combos_into_phiii_melanoma_trials_1175878

    Selina McKee PHARMATIMES
    07 Nov 2016
    Share Share
    NICE nods for Tagrisso, Cimzia and Zepatier
    NICE nods for Tagrisso, Cimzia and Zepatier

    http://www.pharmatimes.com/news/nice_nods_for_tagrisso,_cimzia_and_zepatier_1174814

    Selina McKee PHARMATIMES
    27 Oct 2016
    Share Share
    Roche shares slip as profits miss expectations
    Roche shares slip as profits miss expectations

    http://www.pmlive.com/news/sales/2016/january/roche_shares_slip_as_profits_miss_expectations_917938

    Phil Taylor PM LIVE
    29 Jan 2016
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-2024-05-06

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search